Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of Concern

14 Oct 2022

Abstract excerpt

Severe Acute Respiratory Syndrome Coronavirus 2 is the causal pathogen of coronavirus disease 2019 (COVID-19). The emergence of new variants with different mutational patterns has limited the therapeutic options available and complicated the development of effective neutralizing antibodies targeting the spike (S) protein. Variable New Antigen Receptors (VNARs) constitute a neutralizing antibody technology that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Monoclonal and Polyclonal Antibodies Research
Share to Respiratory viral infections research
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36293124
DOI: 10.3390/ijms232012267

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of ConcernPMID 36293124Read ↗

Antibody Cocktail Exhibits Broad Neutralization against SARS-CoV-2 and SARS-CoV-2 variantsSemantic proximity Read ↗

Bivalent binding of a fully human IgG to the SARS-CoV-2 spike proteins reveals mechanisms of potent neutralizationSemantic proximity Read ↗

Broad Neutralization Activity of SARS-CoV-2 Antibody is Achieved by Coordinated Recognition of Virus Vulnerable SiteSemantic proximity Read ↗

Single domain shark VNAR antibodies neutralize SARS-CoV-2 infection in vitroSemantic proximity Read ↗

Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escapeSemantic proximity Read ↗

A SARS-CoV-2 Neutralizing Antibody Selected from COVID-19 Patients by Phage Display is Binding to the ACE2-RBD Interface and is Tolerant to Known RBD MutationsSemantic proximity Read ↗

ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concernSemantic proximity Read ↗

Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylacticsSemantic proximity Read ↗

Neutralizing antibodies targeting SARS-CoV-2 spike proteinSemantic proximity Read ↗

Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variantsSemantic proximity Read ↗

Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2Semantic proximity Read ↗

Cross-neutralization antibodies against SARS-CoV-2 and RBD mutations from convalescent patient antibody librariesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.